[Experimental evaluation of synergism of cisplatin with L-lysine-alpha-oxidase].

Abstract

Synergism effects of cisplatin and L-lysine-alpha-oxidase (LO), while sequential (no interval) administration of drugs depends on the tumor model and duration of treatment. Synergism is identified at intraperitoneal daily (during 3 days) administration of cisplatin to experimental animals in single doses of 1.5 or 3.0 mg/kg and intravenously 5-fold after 48 h administration of LO and also administered intravenously in cumulative doses of 300-600 E / kg discretely, the first dose--doubled. Synergism of cisplatin and LO is showed by significant (p < 0.05) therapeutic gain against cisplatin at such indicators as increased survival of mice with P388 tumor and increased inhibition of primary tumor melanoma B16.

• Authors: V S Pokrovskiĭ, E V Lukasheva, E M Treshchalina
• Journal: Voprosy onkologii (Vopr Onkol) Vol. 60 Issue 1 Pg. 90-3 ( 2014) ISSN: 0507-3758 [Print] Russia (Federation)
• PMID: 24772623 (Publication Type: English Abstract, Journal Article)

Chemical References

• Amino Acid Oxidoreductases
• L-lysine oxidase
• Cisplatin

Topics

• Amino Acid Oxidoreductases (administration & dosage, pharmacology)
• Animals
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, pharmacology)
• Cisplatin (administration & dosage, pharmacology)
• Drug Screening Assays, Antitumor
• Drug Synergism
• Female
• Leukemia P388 (drug therapy)
• Male
• Melanoma, Experimental (drug therapy)
• Mice
• Mice, Inbred C57BL
• Mice, Inbred DBA
• Survival Analysis
• Treatment Outcome